Adezmapimod (SB203580)

目录号:S1076 别名: RWJ 64809, PB 203580

仅限科研使用

Adezmapimod (SB203580, RWJ 64809, PB 203580) 是一种p38 MAPK抑制剂,在THP-1细胞中IC50为0.3-0.5 μM,对SAPK3(106T)和SAPK4(106T)选择性低10倍,且阻断PKB磷酸化,IC50为3-5 μM。SB203580 可诱导线粒体自噬和细胞自噬。

Adezmapimod (SB203580) Chemical Structure

CAS: 152121-47-6

规格 价格 库存 购买数量
10mM (1mL in DMSO) RMB 1565.11 现货
RMB 1195.54 现货
RMB 3864.74 现货
大包装 有超大折扣
大剂量询单有大折扣!

今日订购,明日送达 全国免运费 分装免费 分装成小规格产品(单支最小为1mg)
如1支10mg产品可分装为10支1mg产品

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Adezmapimod (SB203580)发表文献782篇:

产品安全说明书

p38 MAPK抑制剂选择性比较

相关p38 MAPK产品

生物活性

产品描述 Adezmapimod (SB203580, RWJ 64809, PB 203580) 是一种p38 MAPK抑制剂,在THP-1细胞中IC50为0.3-0.5 μM,对SAPK3(106T)和SAPK4(106T)选择性低10倍,且阻断PKB磷酸化,IC50为3-5 μM。SB203580 可诱导线粒体自噬和细胞自噬。
特性 SB203580是第一个被报道的p38抑制剂。
靶点
p38 MAPK [1]
(THP-1 cells)
PKB [1]
(THP-1 cells)
0.3 μM-0.5 μM 3 μM-5 μM
体外研究

SB203580作用于人类T细胞,鼠CT6 T细胞, 或BAF F7 B细胞,抑制IL-2诱导的增殖,IC50为3-5 μM。SB203580也抑制IL-2诱导的p70S6K激活, IC50 > 10 μM。SB203580也抑制PDK1活性,IC50为3-10 μM,这种抑制存在剂量依赖性。[1]SB203580抑制MAPKAPK2中p38-MAPK的刺激,IC50 为0.07 μM, 然而抑制完整SAPK/JNK活性时,IC50为3-10 μM。SB203580 高浓度时激活ERK通路,随后增强NF-κB转录活性。[2]SB203580作用于人类肝癌细胞(HCC),诱导自体吞噬。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC12 MlraT4lv[XOnIFHzd4F6 MnH6NVAh|ryP NYXKeIZOOTVibXnu MlP0TY5pcWKrdIOgdFM5KE2DUDDrbY5ie2Vid3n0bEBKSzVyIH;mJFAvPiEQvF2= NXjCZo5nRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxN{e1NFU4Pyd-N{e1NFU4PzxxYU6=
THP-1 NEfmNJJHfW6ldHnvckBCe3OjeR?= MV7Jcohq[mm2czDMVHMucW6mdXPl[EBVVk[jbIDoZUBxem:mdXP0bY9vKHerdHigTWM2OCCxZjCwMlE3KM7:TR?= MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDN{NUe2PEc,OTh|MkW3Olg9N2F-
PBMC Ml7NSpVv[3Srb36gRZN{[Xl? M3P1V|E2KG2rbh?= MV;EUXNQ NFTV[oJKdmirYnn0d{B1cGVicnXs[YF{\SCxZjDpcpRmemyndXvpck0yNWKndHGge4l1cCCLQ{WwJI9nKDBwMEO3JO69VQ>? MoPhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ|NkGzPVYoRjF{M{[xN|k3RC:jPh?=
SW1353 MXnGeY5kfGmxbjDBd5NigQ>? NXXm[JhsOSCq NGLlO5BFVVOR NULXT41LUW6qaXLpeJMhUUxvNjDwdo9lfWO2aX;uJJdqfGhiSVO1NEBw\iByLkC1JO69VQ>? MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTF2MEe0NUc,OTFzNEC3OFE9N2F-
Hela NF\4TG1HfW6ldHnvckBCe3OjeR?= NWjlO|RvTE2VTx?= NIHjXI9KdmirYnn0d{BV[XRvaX7keYNm\CCKSW[xJGxVWiC2cnHud4FkfGm4YYTpc44hcW5iaIXtZY4hUGWOYTDj[YxteyC5aYToJGlEPTBib3[gNE4yKM7:TR?= NIG4OZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEmyOlcyOSd-MUi5NlY4OTF:L3G+
PC12 MWfGeY5kfGmxbjDBd5NigQ>? NVO3RXJ{OTBizszN MnrMSG1UVw>? MXLBZ5RqfmG2ZYOgUpJnOi:DUlWgbY4hemG2IGDDNVIh[2WubIOgZZN{\XO|ZXSgZZMhUE9vMTDwdo91\WmwIHnu[JVkfGmxbh?= M3zlOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{S1Olg2Lz5{MUO0OVY5PTxxYU6=
RAW 264.7 MkfNR5l1d3SxeHnjJGF{e2G7 M4\jVlEzNjVizszN MVmxNog> NW[xfI97TE2VTx?= M4DMU2Jtd2OtczDs[ZRp[WxidH;4bY4udWWmaXH0[YQh[3m2b4TvfIlkcXS7 M{X6UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NEi1OVA1Lz5zN{S4OVUxPDxxYU6=
HCA2 MnPuSpVv[3Srb36gRZN{[Xl? Mo\0Nk42KM7:TR?= NXrUUWhUUW6qaXLpeJMheDN6IH3l[IlifGWmIF3LNkBi[3SrdnH0bY9v Mn7tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd7NkS3PFAoRjF5OU[0O|gxRC:jPh?=
U937 MULGeY5kfGmxbjDBd5NigQ>? M1;wfmlvcGmkaYTzJGpCUy2vZXTpZZRm\CCrboTldoZmem:wLXfhcY1iN2GwaYPvcZlkcW5vaX7keYNm\CCVdHH0NUBxcG:|cHjvdplt[XSrb36= NGDDU5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEG1O|EzOid-MUixOVcyOjJ:L3G+
U937 NUXQWG9pTnWwY4Tpc44hSXO|YYm= M2L3fWlvcGmkaYTzJGpCUy2vZXTpZZRm\CCrboTldoZmem:wLXfhcY1iN2GwaYPvcZlkcW5vaX7keYNm\CCyM{igdIhwe3Cqb4L5cIF1cW:w NHXVNJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEG1O|EzOid-MUixOVcyOjJ:L3G+
hESCs NX30W3AyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrHOUDPxE1? MmT6SG1UVw>? NWfOT2syUW6mdXPld{Bk[XKmaX;tfY9o\W6rYzDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cA>? NVe0V3ZNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NFI{QTlpPkKzOlAzOzl7PD;hQi=>
RAW264.7 NFfqTnVHfW6ldHnvckBCe3OjeR?= MYKxNEDPxE1? M{fJbGlv\HWlZYOgZY51cWmwZnzhcY1ifG:{eTDhZ5Rqfmm2eTDifUBqdmirYnn0bY5oKEmOLUJOtkBz\WynYYPl MnuwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5OUGwO|goRjJ|N{mxNFc5RC:jPh?=
RAW264.7 NIG2[4dHfW6ldHnvckBCe3OjeR?= NXOz[2d1OTBizszN M1nEWWlv\HWlZYOgZY51cWmwZnzhcY1ifG:{eTDhZ5Rqfmm2eTDifUBqdmirYnn0bY5oKGmQT2OgdoVt\WG|ZR?= MnniQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5OUGwO|goRjJ|N{mxNFc5RC:jPh?=
RAW264.7 MoLzSpVv[3Srb36gRZN{[Xl? MnTFNVAh|ryP Mm\HTY5lfWOnczDhcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHL5JIlvcGmkaYTpcochVk9icnXs[YF{\Q>? MoHvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5OUGwO|goRjJ|N{mxNFc5RC:jPh?=
RAW264.7 M4Szb2Z2dmO2aX;uJGF{e2G7 NHj1V5UyOCEQvF2= NYPrOmxyUW6qaXLpeJMhVFCVLXnu[JVk\WRicEO4JG1CWEticHjvd5Bpd3K7bHH0bY9v NWDsSFhxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNVYxPTdpPkK0NFE3ODV5PD;hQi=>
IEC-18 M1rEbGZ2dmO2aX;uJGF{e2G7 M{HCOFExKM7:TR?= NYXBdZdEUW6qaXLpeJMhVFCVLXnu[JVk\WRicEO4JG1CWEticHjvd5Bpd3K7bHH0bY9v NFz6TIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e1PFEyOCd-MkO3OVgyOTB:L3G+
Sf9 NH3wPHhHfW6ldHnvckBie3OjeR?= MUWzNEBucW6| M{HxeGlvcGmkaYTpc44hd2ZiZoXscE1t\W6pdHigSmxCTy14SHnzMXRGXiC2YXfn[YQhcHWvYX6gVmlROiCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDheZRweGixc4Doc5J6dGG2aX;uJJBz\S2rbnP1ZoF1\WRiZn;yJFMxKG2rboOg[o9tdG:5ZXSgZpkhcW6ldXLheIlwdiC5aYToJGFVWCCob4KgNkBpenNiYomgRWRRNUeubzDhd5NigSxiSVO1NEA:KDBwMEGg{txONg>? NGfjWng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkS1OVY2PCd-Mk[0OVU3PTR:L3G+
sf21 MYfGeY5kfGmxbjDhd5NigQ>? M4L5fGJqdmSrbnegZYZncW6rdImgeI8hf2muZDD0fZBmKGi3bXHuJIJqd3SrbjDsZYJmdGynZDDwN|gh[WyyaHGgLFkhfG9iM{WyJJJme2mmdXXzLUBmgHC{ZYPz[YQhcW5ic3[yNUBqdnOnY4SgZ4VtdHNiU2DSJIFv[Wy7c3nzMEBM\CB;IECuNFIyPyEQvF2u NGC3OJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEizOFQ{OSd-Mki4N|Q1OzF:L3G+
PBMC NVzDVldOTnWwY4Tpc44h[XO|YYm= NIDlZXBKdmirYnn0bY9vKG:oIGTOSk1idHCqYTDwdo9lfWO2aX;uJIJ6KGyrcH;wc4x6e2GlY3jhdoll\S2|dHnteYxifGWmIHj1cYFvKHCncnnwbIVz[WxiYnzvc4QhdW:wb371Z4xm[XJiY3XscJMtKEmFNUCgQUAxNjB{NTFOwG0v MnrmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwQTh5M{ezNEc,QTh5M{ezNFww[T5?
PBMC MkjjSpVv[3Srb36gZZN{[Xl? NYXYNoROUW6qaXLpeIlwdiCxZjDMVHMue3SrbYXsZZRm\CCWSDvOSk1idHCqczDwdo9lfWO2aX;uJIJ6KGi3bXHuJJBmemmyaHXyZYwh[myxb3SgcY9vd263Y3zlZZIh[2WubIOgLHBDVUO|KTygTWM2OCB;IECuNFI2KM7:TT6= NVPkUIFGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxOUe4OFA6Oyd-OUe4OFA6OzxxYU6=
PBMC NX3OVpl2TnWwY4Tpc44h[XO|YYm= MlqxTY5pcWKrdHnvckBw\iCyM{igUWFRKGurbnHz[UBz\WyjdHXkJHRPTi2jbIDoZUBz\WynYYPlJIZzd21icHXybZBp\XKjbDDicI9w\CCvb37vcpVkdGWjcjDj[YxteyBqUFLNR{ktKEmFNUCgQUAxNjB|NzFOwG0v NUfEZ3k3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUKwOlE5PzZpPkGyNFYyQDd4PD;hQi=>
PBMC NUDpW5BKTnWwY4Tpc44h[XO|YYm= NH\XWVNKdmirYnn0bY9vKG:oIFzQV{1qdmS3Y3XkJGlNOS2kZYThJJBzd2S3Y4Tpc44hcW5iaIXtZY4heGW{aYDo[ZJidCCkbH;v[EBud26xboXjcIVieiClZXzsd{hRSk2FczmsJGlEPTBiPTCwMlA1QCEQvF2u NG\Xb4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi97N{i0NFk{Lz57N{i0NFk{RC:jPh?=
SW1353 NVvuRndzTnWwY4Tpc44h[XO|YYm= NUHq[2wyS2:vcH;1coQhf2G|IHX2ZYx2[XSnZDDmc5IhcXS|IHHibYxqfHlidH:gbY5pcWKrdDDJUE03KHC{b3T1Z5Rqd25iaX6gV3cyOzV|IHPlcIx{KHS{ZXH0[YQhf2m2aDDjfZRwc2mwZYOgTWwuOSCjbnSgWG5HNCCLQ{WwJF0hOC5yNTFOwG0v MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODl7OUS2O{c,OTB7OUm0Olc9N2F-
SW1353 M3\5OmZ2dmO2aX;uJIF{e2G7 NGLtfXVKdmirYnn0bY9vKG:oIGTOSkBidmRiSVytNUBqdmS3Y3XkJGlNNTZicILv[JVkfGmxbjDpckBpfW2jbjDjbI9v\HKxLYPhdoNwdWFiU2egNVM2OyClZXzsd{whUUN3MDC9JFAvODVizszNMi=> M1vYR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyOUm5OFY5Lz5zMEm5PVQ3QDxxYU6=
THP1 M3jCT2Z2dmO2aX;uJIF{e2G7 MYHJcohq[mm2aX;uJI9nKEySUz3zeIlufWyjdHXkJGlNOSCycn;keYN1cW:wIHnuJIh2dWGwIGTIVFEh[2WubIOsJGlEPTBiPTCwMlA2KM7:TT6= NInIS|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEC3O|M3Oyd-MUiwO|c{PjN:L3G+
THP1 MXvGeY5kfGmxbjDhd5NigQ>? NFTGbWlKdmirYnn0bY9vKG:oIFzQV{1{fGmvdXzheIVlKFSQRnHsdIhiKHC{b3T1Z5Rqd25iaX6gbJVu[W5iVFjQNUBk\WyuczygTWM2OCB;IECuNFUh|ryPLh?= NFzMbWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEC3O|M3Oyd-MUiwO|c{PjN:L3G+
THP1 M{HxPWZ2dmO2aX;uJIF{e2G7 NELF[YFKdmirYnn0bY9vKG:oIFzQV{1qdmS3Y3XkJJR2dW:{IH7lZ5Jwe2m|IH\hZ5Rwei2jbIDoZUApXE6ILXHsdIhiMSCycn;keYN1cW:wIHnuJHRJWC1zIHPlcIx{NCCHQ{WwJF0hOC5yNjFOwG0v NYXYdGdDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUKwPFY1QDVpPkGyNFg3PDh3PD;hQi=>
THP1 NX7NRoQ{TnWwY4Tpc44h[XO|YYm= M3j3eWlvcGmkaYTpc44hd2ZidIXtc5IhdmWlcn;zbZMh\mGldH;yJIFteGijIILlcIVie2ViYomgWGhRNTFiY3XscJMtKEmFNUCgQUAxNjB5IN88UU4> M1v3VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NkW4PFU2Lz5zNU[1PFg2PTxxYU6=
monocytic cell MXnGeY5kfGmxbjDhd5NigQ>? MV;Jcohq[mm2b4L5JIFkfGm4aYT5JIFo[Wmwc4SgWG5HNWGucHjhJJBzd2S3Y4Tpc44hfXOrbnegcIlxd3CxbInzZYNkcGG{aXTlJJN1cW23bHH0[YQhcHWvYX6gcY9vd2O7dHnjJINmdGy|LDDJR|UxKD1iMD6wO|Ih|ryPLh?= NYLVelFXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK3Nlk3OzdpPkGyO|I6PjN5PD;hQi=>
THP1 MXTGeY5kfGmxbjDhd5NigQ>? M4f0Z2lvcGmkaYTvdpkh[WO2aY\peJkh[WejaX7zeEBNWFNvc4TpcZVt[XSnZDDUUmYu[WyyaHGgdJJw\HWldHnvckBqdiCqdX3hckBud26xY4n0bYMh[2WubIOgLHRJWC1zKTygTWM2OCB;IECuNFczKM7:TT6= Mn[xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTVzM{m3OFkoRjF3MUO5O|Q6RC:jPh?=
THP-1 NVO5[3BnTnWwY4Tpc44h[XO|YYm= NVnOemFRUW6qaXLpeI9zgSCjY4Tpeol1gSCjZ3HpcpN1KGyrcH;wc4x6e2GlY3jhdoll\SC|dHnteYxifGWmIGTOSk1idHCqYTDwdo9lfWO2aX;uJIlvKFSKUD2xJINmdGy|IDjoeY1idiCvb37vZ5l1cWNiY3XscJMqNCCLQ{WwJF0hOC5yN{Kg{txONg>? MlfIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV6M{ezNVAoRjF3OEO3N|ExRC:jPh?=
THP1 MlPxSpVv[3Srb36gZZN{[Xl? NXL6PGR1UW6qaXLpeIlwdiCxZjDMVHMue3SrbYXsZZRm\CCWTl\hcJBp[SCycn;keYN1cW:wIHnuJHRJWDFiY3XscJMtKEmFNUCgQUAxNjB5MjFOwG0v MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjd3MEO2O{c,OTZ5NUCzOlc9N2F-
PBMC NEPpbIdHfW6ldHnvckBie3OjeR?= MUHJcohq[mm2aX;uJI9nKHO2YYDofYxw[2:lY3HsJIVvfGW{b4TvfIlvKEJqU1XCLUB{fGmvdXzheIVlKHS3bX;yJI5m[3Kxc3nzJIZi[3SxcjDhcJBp[SBqVF7GMYFteGijKTDwdo9lfWO2aX;uJIJ6KGi3bXHuJJBmemmyaHXyZYwh[myxb3SgcY9vd263Y3zlZZIh[2WubIOoVGJOS3NrLDDJR|UxKD1iMD6xOkDPxE1w NVH6NY95RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxOUe4OFA6Oyd-OUe4OFA6OzxxYU6=
PBMC NHjaO2RHfW6ldHnvckBie3OjeR?= NUHF[VVvS2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JIxqeG:yb3z5d4Fk[2ijcnnk[UBqdmS3Y3XkJHRPTi2jbIDoZUBz\WynYYPlJJdieyCmZYTldo1qdmWmIHnuJIh2dWGwIIDldolxcGW{YXygZoxwd2RibX;uc452[2ynYYKgZ4VtdHNuIFnDOVAhRSByLkG5JO69VS5? MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTR3NEKzNUc,OTV2NUSyN|E9N2F-
Sf9 NWP0dZVKTnWwY4Tpc44h[XO|YYm= NV[1Ro5VUW6qaXLpeIlwdiCxZjDmeYxtNWynbnf0bEBHVEGJLU\IbZMuXEWYIITh[4dm\CCqdX3hckBTUVB{IHX4dJJme3OnZDDpckBU\jliY3XscJMh[nliZnz1c5Jme2OnboSgdI9t[XKrenH0bY9vKGG|c3H5MEBKSzVyIE2gNE4zKM7:TT6= MlHaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ2NUW2OVQoRjJ4NEW1OlU1RC:jPh?=
HEK293F NX;CWJVsTnWwY4Tpc44h[XO|YYm= M2[3cmlvcGmkaYTpc44hd2Zic3;kbZVuKGG{c3XuZZRmKGGldHn2ZZRm\CCQLYTldo1qdmGuIFfTWE11[WepZXSgRpJ2\2mjIH3hcIF6cSCPUFuxJIV5eHKnc4Pl[EBqdiCKRVuyPVNHKGOnbHzzJJV{cW6pIF\BUU1xOzi2aXTlJIF{KHO3YoP0doF1\SCkeTDJUWFRKGG|c3H5MEBKSzVyIE2gNE4zOiEQvF2u NETuO209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW0NVM3Oid-Mkm1OFE{PjJ:L3G+
HEK-293 MmDCSpVv[3Srb36gZZN{[Xl? NFLTdGRKdmirYnn0bY9vKG:oIGLJVFJMKGmwIF3EVE1{fGmvdXzheIVlKEiHSz2yPVMh[2WubIOgc5Zmei2neIDy[ZN{cW6pIF7PSFIh[XO|ZYPz[YQh[XNiSVy4JJNm[3KndHnvckwhUUN3MDC9JFAvOjVizszNMi=> MoLFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzMEm4OlcoRjJ5MUC5PFY4RC:jPh?=
whole blood cell MnjLSpVv[3Srb36gZZN{[Xl? MXWwMlAyKHSxIEGwNEB2VQ>? NUnhO|lwUW6qaXLpeIlwdiCxZjDwN|guemWuYYTl[EBKVDFvYnX0ZUBz\WynYYPlJIJ6KHeqb3zlJIJtd2:mIHPlcIx{KGG2IEGwJIUuPCC2bzCxNEBmNThiTTygTWM2OCB;IECuN|Uh|ryPLh?= M2HKV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{OEWyO|U1Lz5zMki1Nlc2PDxxYU6=
PBMC M4\6R2Z2dmO2aX;uJIF{e2G7 Mme5TY5pcWKrdHnvckBw\iCyM{igUWFRKGurbnHz[UBz\WyjdHXkJHRPTi2jbIDoZUBz\WynYYPlJIZzd21icHXybZBp\XKjbDDicI9w\CCvb37vcpVkdGWjcjDj[YxteyBqUFLNR{ktKEmFNUCgQUAxNjV7IN88UU4> MnrxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJyNkG4O|YoRjF{ME[xPFc3RC:jPh?=
PBMC NHrJcZZHfW6ldHnvckBie3OjeR?= MXTJcohq[mm2aX;uJI9nKHSqZTDy[Yxm[XOnIH;mJJR2dW:{IH7lZ5Jwe2m|IH\hZ5RweiCjbIDoZUBnem:vIIDldolxcGW{YXygZoxwd2RibX;uc452[2ynYYKgZ4VtdHNuIFnDOVAhRSByLkW5JO69VS5? Mof6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ|NkGzPVYoRjF{M{[xN|k3RC:jPh?=
PBMC MX7GeY5kfGmxbjDhd5NigQ>? NFXIb|ZKdmirYnn0c5J6KGGldHn2bZR6KGGpYXnud5QhXE6ILXHsdIhiKHKnbHXhd4UhcW5iUFLNJINmdGy|LDDJR|UxKD1iMD61PUDPxE1w NXy4cmpsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK4OVI4PTRpPkGyPFUzPzV2PD;hQi=>
whole blood cell NV3kVog1TnWwY4Tpc44h[XO|YYm= NULpNZdWOC5yMTD0c{AyODBidV2= NYPBOG9xUW6qaXLpeIlwdiCxZjDwN|guemWuYYTl[EBVVkZvYXzwbIEhemWuZXHz[UBjgSC5aH;s[UBjdG:xZDDj[YxteyCjdDCxNEBmNTRidH:gNVAh\S16IF2sJGlEPTBiPTCwMlk1KM7:TT6= MoT2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ6NUK3OVQoRjF{OEWyO|U1RC:jPh?=
BMDC MVHBcpRqcW6obHHtcYF1d3K7IHHzd4F6 MWKxJIhz M3nW[2FvfGmrbn\sZY1u[XSxcomgZYN1cX[rdImgbY4hSzV5QlyvOkBud3W|ZTDCUWREKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gUHBUNWmwZIXj[YQhUUxvNjDwdo9lfWO2aX;uJJBz\WmwY4XiZZRm\CCob4KgNUBpeiCycnnvdkB1dyCOUGOtd5RqdXWuYYTpc44hdWWjc4Xy[YQh[W[2ZYKgNVghcHK|IHL5JGVNUVODLDDJR|UxKD1iMz61JO69VS5? MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB2N{K1PUc,OjRyNEeyOVk9N2F-
BMDC MYPBcpRqcW6obHHtcYF1d3K7IHHzd4F6 NWq2R3RZOSCqch?= NUHqcY9lSW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCFNUfCUE83KG2xdYPlJGJOTENiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBNWFNvaX7keYNm\CCLTD2xNkBxPDBicILv[JVkfGmxbjDwdoVqdmO3YnH0[YQh\m:{IEGgbJIheHKrb4KgeI8hVFCVLYP0bY12dGG2aX;uJI1m[XO3cnXkJIFnfGW{IEG4JIhzeyCkeTDFUGlUSSxiSVO1NEA:KDVizszNMi=> MlvmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNEeyOVkoRjJ2MES3NlU6RC:jPh?=
HEK-293 M4nNfGZ2dmO2aX;uJIF{e2G7 Mon6TY5pcWKrdHnvckBw\iCUSWCyT{BqdiCSYX2yR3NMPC2|dHnteYxifGWmIFjFT{0zQTNiY3XscJMhd3[ncj3lfJBz\XO|aX7nJHRNWjJiYYPz[ZN{\WRiYYOgTWw5KHOnY4LleIlwdixiSVO1NEA:KDZwM{Gg{txONg>? M4LMeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUC5PFY4Lz5{N{GwPVg3PzxxYU6=
BMDC MUPBcpRqcW6obHHtcYF1d3K7IHHzd4F6 NXTEO3k5OSCqch?= NWTEb2h2SW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCFNUfCUE83KG2xdYPlJGJOTENiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBNWFNvaX7keYNm\CCWTl\hcJBp[SCycn;keYN1cW:wIIDy[Ylv[3WkYYTl[EBnd3JiMTDodkBxemmxcjD0c{BNWFNvc4TpcZVt[XSrb36gcYVie3W{ZXSgZYZ1\XJiMUigbJJ{KGK7IFXMTXNCNCCLQ{WwJF0hPy53IN88UU4> NVLzR282RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOFczPTlpPkK0NFQ4OjV7PD;hQi=>
macrophage-like cell MUnBcpRqcW6obHHtcYF1d3K7IHHzd4F6 NVmwc2pXOzBibXnudy=> M4nBd2FvfGmrbn\sZY1u[XSxcomgZYN1cX[rdImgbY4hcHWvYX6gTGwuPjBiZHXybZZm\CCvYXPyc5Bp[WenLXzpb4Uh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDMVHMucW6mdXPl[EBVVk[jbIDoZUBxem:mdXP0bY9vKHS{ZXH0[YQhOzBibXnud{Bj\W[xcnWgUHBUKHO2aX31cIF1cW:wIH3lZZN2emWmIHHmeIVzKDJ2IHjyd{BjgSCHTFnTRUwhUUN3MDC9JFgvPiEQvF2u MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzhzMUC4PUc,OjN6MUGwPFk9N2F-
WS NH;pd4dHfW6ldHnvckBie3OjeR?= M2PrVFIvPSC3TR?= MYHJcohq[mm2aX;uJI9nKGGwaYPvcZlkcW5vaX7keYNm\CCSM{itZYxxcGFiYXP0bZZifGmxbjDpckBpfW2jbjDoeY1idiCWRWLUMYludW:{dHHsbZNm\CCZUzDj[YxteyCjc4Pld5Nm\CCjczDIV3AzPyCyaH;zdIhwenmuYYTpc44h[XRiMj61JJVO MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ3OUi3NUc,OTd4NUm4O|E9N2F-
WS M1jMOWZ2dmO2aX;uJIF{e2G7 M3T6UWlvcGmkaYTpc44hd2ZiTVuyJI1m\GmjdHXkJGhUWDJ5IIDoc5NxcG:{eXzheIlwdiCrbjDpcY1wenSjbHnz[YQhX1NiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGYu[WO2aX6gd5Rz\XO|IH\pZpJmew>? MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzl4NEe4NEc,OTd7NkS3PFA9N2F-
WS MoT0SpVv[3Srb36gZZN{[Xl? M3zyWGlvcGmkaYTpc44hd2ZicEO4JI1m\GmjdHXkJG1MOiCjY4TpeoF1cW:wIHnuJHdUKGOnbHzz M1m2XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5OU[0O|gxLz5zN{m2OFc5ODxxYU6=
A673 NYXVWmM2eUiWUzDhd5NigQ>? NITY[GJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?= MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Saos-2 NULkU2lVeUiWUzDhd5NigQ>? NYnD[ZpReUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=> MoTJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-37 M2PLXJFJXFNiYYPzZZk> NGHibGVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStN|ch[2WubIO= NH3qcnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
RD M1OzSJFJXFNiYYPzZZk> NYfzXGdueUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLEJINmdGy| M{HH[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12 M3:1[JFJXFNiYYPzZZk> MXXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN? NFvVXmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
OHS-50 NEHL[5JyUFSVIHHzd4F6 M2HhNpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO= NUHwc4psRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2 M1\tUpFJXFNiYYPzZZk> NHS4XodyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=> M3j5bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC NH7IVHFyUFSVIHHzd4F6 NWjsd2hweUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM> MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Assay
Methods Test Index PMID
Western blot phospho-p38 / p38 p-ASK1 / ASK1 / P-JNK / p-MKK4 / p-ERK phospho-MK2(T334) / phospho-HSP27(S82) / phospho-Akt(T308) / phospho-Akt(S473) 25747578 24082073 21737674
Immunofluorescence dsRNA / hnRNP A1 25747578
Growth inhibition assay Cell viability 23001390
体内研究 SB203580作用于缺血性损伤,保护猪的心肌层。[4] SB203580有效保护携带系统性红斑狼疮的MRL/lpr鼠和治疗疾病。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

  • 细胞受体激酶磷酸化实验 :

    4 μg羊PKBα抗体固定在25 μL蛋白G-亲和层析柱上过夜(或1.5 小时) ,用Buffer A (50 mM Tris, pH 为7.5, 1 mM EDTA, 1 mM EGTA, 0.5 mM Na3VO4, 0.1% β-巯基乙醇,1% Triton X-100, 50 mM NaF, 5 mM焦磷酸钠, 0.1 mM苯甲磺酰氟, 1 μg/mL抑蛋白酶肽, 抑肽素, 亮抑酶肽,及1 μM微囊藻素)冲洗。固定的PKB抗体和0.5 ml细胞溶解物温育1.5小时,用含0.5 M NaCl的0.5 mL Buffer A冲洗三次, 再用0.5 mL Buffer B (含50 mM Tris-HCl, pH为7.5, 0.03% (w/v) Brij-35, 0.1 mM EGTA, 及 0.1% β-巯基乙醇)冲洗二次,最后用100 μL实验稀释buffer冲洗二次; 5×实验稀释buffer包含100 mM MOPS, pH为7.2, 125 mM β-甘油磷酸, 25 mM EGTA, 5 mM原钒酸钠, 及5 mM DTT。10 μL实验稀释buffer,40 μM蛋白激酶A抑制肽, 100 μM PKB-特定底物肽,及10 μCi [γ-32P]ATP,加到PKB酶免疫复合物中。反应在室温下震荡温育20分钟,40 μL反应物转移到其他试管中,加入20 μL 40%三氯乙酸,终止反应。在室温下混合,温育5分钟,40 μL转移到P81磷酸纤维素纸上,亲和处理30秒 。P81纸在0.75%磷酸中洗三次,然后在室温下加到丙酮中。 使用闪烁计数器测量γ-32P 渗透率。

细胞实验:

[1]

  • Cell lines: CT6细胞, BA/F3 F7细胞
  • Concentrations: 0-30 μM
  • Incubation Time: 1小时
  • Method:

    CT6细胞和BA/F3 F7细胞在RPMI培养基中冲洗三次,然后培养在含5%胎牛血清,生长因子,抗生素,β-巯基乙醇的RPMI培养基中。2-5×106个CT6细胞悬浮在含5%胎牛血清的2 ml RPMI培养基上, 用SB203580预处理。然后加入20 ng/ml重组人类IL-2,在37 oC下刺激细胞5分钟,离心30秒,溶解于合适buffer中。稳定表达IL-2受体β链缺失突变的BA/F3细胞维持在含谷氨酸,5%胎牛血清和0.2 μg/mL G418的RPMI培养基中。大规模冲洗细胞,过夜处理,在用IL-2激活前再次冲洗。通过测定[3H]胸苷的渗透率,进行细胞增殖实验。

动物实验:

[5]

  • Animal Models: 携带系统性红斑狼疮的雌性MRL/lpr鼠和雌性C57BL/6鼠
  • Dosages: 0.4mL/天
  • Administration: 口服处理

溶解度(25°C)

体外

体内

从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O

5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 377.43
化学式

C21H16FN3OS

CAS号 152121-47-6
储存条件 3年 -20°C(避光) 粉状

动物体内配方计算器(澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)

mg/kg g μL

第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)

% DMSO % % Tween 80 % ddH2O
%DMSO %

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于μL DMSO溶液(母液浓度mg/mL,:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);

体内配方配制方法:μL DMSO母液,加入μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入μL ddH2O,混匀澄清。

体内配方配制方法:μL DMSO母液,加入μL Corn oil,混匀澄清。

注意:1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

摩尔浓度计算器

质量 浓度 体积 分子量

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

* 必填项

请输入您的姓名
请输入您的邮箱地址 请输入一个有效的邮箱地址
请写点东西给我们